NSABP C-07 — Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07

Phase 3 · 2007 · Colon Cancer

Design

Randomized trial comparing weekly bolus 5-FU/leucovorin versus the same regimen plus oxaliplatin (FLOX) as adjuvant therapy after colon resection.

Population

Patients with resected stage II and III colon cancer.

Primary Endpoint

Disease-free survival

Key Result

Adding oxaliplatin (FLOX) improved 3-year disease-free survival (76.1% vs 71.8%; HR 0.80, 95% CI 0.69-0.93; P=0.004).

Guideline Impact

Oxaliplatin-based adjuvant therapy standard for stage III colon cancer in NCCN guidelines